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 The performance of extracellular matrix (ECM) biological scaffolds for the treatment of 
volumetric muscle loss (VML) has shown promising results with regenerating native muscle in 
animal models and human patients. However, the limitations of these scaffolds include non-
specific characteristics based on the original parameters of the muscle that is lost and this is why 
our group chose to characterize human skeletal ECM. By understanding the characteristics of the 
native human skeletal ECM, more desired queues for the biological scaffolds being used to treat 
VML can be provided. Upper limb and lower limb skeletal muscles were commercially obtained, 
decellularized using common techniques, and underwent biochemical and physical assessment. 
The presence of collagen and glycosaminoglycans were identified within the human skeletal 
ECM. The mechanical strength and overall alignment of the human skeletal ECM was also 
evaluated. The human skeletal ECM supported an in-vivo degradation assessment and showed 
signs of tolerance within the in-vivo model. The results of the current study suggest that the 
location and gender of the original muscle indeed plays a significant role between the two ECM 
muscle types within some of the characterization tests. We believe we are the first group to 
characterize human skeletal muscle ECM with the intent to mimic these parameters. A future 
direction for this project would be to incorporate these parameters found within this study into 
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1.  Introduction  
 
1.1 Muscle and Acute Muscle Injuries/Self Repair 
 
Muscle is a fibrous tissue that contributes to different voluntary and involuntary 
movements throughout the body. Muscle can be grouped in three different categories: skeletal 
muscle, smooth muscle, and cardiac muscle. The focus of this study is within the scope of 
skeletal muscle, which is termed a voluntary muscle that is anchored to the bones by tendons and 
ligaments. More specifically skeletal muscle is composed of myofibers and connective tissue1. 
Myofibers, capillaries, and nerves are housed within the connective tissue. Its main function to 
skeletal muscle is providing a framework so muscles can contract. The myofibers are the 
components that are interacting with the nerves in order to carry out contraction forces for 
skeletal muscle. The basic structure that groups myofibers into myofibrils is a connective tissue 
structure composed of three different layers or sheets2. The epimysium layer is considered to be 
the outer most layer that holds all of the myofibrils together since it surrounds entire muscle. The 
epimysium layer is the strongest layer within the connective tissue structure that house the 
myofibrils. The epimysium layer is made of multiple fascicles that house the myofibrils. The 
outer layer of the fascicles is the second/middle layer of the connective structure called the 
perimysium. Within the fascicles is the home of the third inner-most layer of the connective 
tissue structure called the endomysium. The endomysium is a dense sheath that surrounds each 
individual myofiber within the myofibril bundle. The extracellular space outside of each 




extracellular matrix (ECM) is composed of multiple cellular and structural components that help 
with muscle repair/regeneration following acute muscle injury. 
Acute muscle injury can occur from multiple sources. For example, strain related muscles 
injuries3, lacerations4, and contusions5 are all injuries that can be repaired by existing muscle 
surrounding the site of injury. The process of muscle self-repair following one of these acute 
injuries follows three main steps. This is a brief review of the main points in muscle self-
repair/regeneration. Muscle self-repair involves more signals than the ones described in this 
study. The first stage in muscle-repair is inflammation at the site of injury6. Leukocytes, mainly 
neutrophils and macrophages are recruited to the site of the injured muscle and start to remove 
necrotic muscle tissue at the injury site by phagocytosis. Evidence suggests macrophages have 
another function within muscle regeneration6. Cultured activated macrophages along with 
skeletal muscle myoblasts from neonatal rats have been shown to increase myoblast number size 
and proliferation. An increase of myotubes were also found within cell cultures containing the 
activated macrophages and myoblasts. This suggests that once an inflammatory response is over 
at the site of injury, macrophages continue to play a role in muscle self-repair. Once the initial 
inflammatory response is over, satellite cells already located between the plasma membrane of 
myofibrils and the endomysium layer become activated at the site of injury7. Satellite cells are 
the “stem cells” for muscle; they are responsible for repair and regeneration of skeletal muscle. 
Activation of satellite cells can be complex. One way these cells are activated is by nitric oxide 
(NO) synthesis. The macrophages that are recruited to the injured muscle site produce NO as a 
side product of phagocytosis of the necrotic muscle tissue. The NO is then synthesized and this 
stimulates the release of hepatocyte growth factor (HGF) that is stored within the ECM of 




satellite cells in the muscle, thus activating satellite cells in response to injury8,9. After satellite 
cells are activated, they must proliferate and differentiate into muscle cells. Proliferation and 
differentiation of the satellite cells into multinucleated myofibers and then into myofibrils is 
achieved through two different signaling pathways. Notch-1 pathways are believed to become 
activated within a satellite cell at the first site of injury and then this pathway immediately starts 
satellite cell proliferation10. Eventually the Notch-1 pathway transitions into the Wnt pathway for 
differentiation of satellite cells11. The satellite cells differentiate into myofibers and then the 
myofibers get bundled together to make myofibrils.   
 
1.2 Severe muscle loss and current treatments 
 
 Muscle that has been severely damaged does not undergo self-repair/regeneration. This 
type of muscle damage is termed volumetric muscle loss (VML) and scar tissue replaces the 
once healthy tissue causing major functional loss at the site of injury. Volumetric muscle loss is 
defined as skeletal muscle that is lost due to trauma that exceeds the muscle’s ability to repair the 
affected site12.  VML mostly occurs from extensive military injuries13, but can also occur from 
extreme sporting accidents, gunshot wounds or birth defects. Treatment is required in order to try 
and improve functional mobility at the site of injury. Current treatment methods for VML 
include removal of scar tissue and the implantation of muscle flaps14. Scar tissue is initially 
removed to help improve the chance of regaining some form of functionality back into the VML 
site. Muscle flap transfers are usually autologous and are taken from the back muscles, since 
these muscles offer a large surface area. The muscle flaps are surgically placed over the VML 




exposed muscle and bone. Patients who undergo muscle flap surgery to treat a VML wound site 
can regain some basic function at the injured site, but usually never regain full function of the 
lost muscle14. Therefore, different experimental methods are being investigated for treatment of 
volumetric muscle.  
 
1.3 New techniques in treating VML 
 
 The main goal when studying these new techniques is to ultimately give the patient full 
function at the VML site and restore native muscle formation. There are two different 
approaches to treating VML that are being studied in current literature. One is using extracellular 
matrix (ECM) derived from existing muscle to help regenerate native muscle within the VML 
site in animal models and extreme human cases 15-18, and the other technique, which is currently 
being investigated in our lab, is using “engineered” ECM19 derived from skeletal muscle cells to 
regenerate native skeletal muscle in a rat animal model.  
 Native ECM is being derived from multiple locations within the body and is being used 
as a treatment method for VML. In one study, rat tibilias anterior (TA) was decellularized and its 
corresponding skeletal ECM was implanted into a VML defect15. The VML criteria for this 
particular study involved removing 20% of the original muscle mass from the TA of their rat 
animal model. The implantation site was observed at 2, 4, and 6 months post-surgery. This group 
did find some evidence of muscle regeneration within the defect site around the 2 and 4 month 
time points. Treatment of VML with decellularized ECM derived components has also been 




(quadriceps) injury16. The patient’s quadriceps injury was treated with a manufactured implant 
that consisted of porcine small intestinal submucosa (SIS) ECM. This material (Restore) was 
commercially obtained from DePuy Orthopaedics, Inc in Warsaw, Indiana. New tissue growth 
was reported after 36 weeks post-surgery, and the patient regained some function at the injury 
site as time progressed. Another VML model treated with decellularized porcine small intestinal 
submucosa ECM was tested within mice, and results observed were similar to those described in 
the previous studies listed above17. A new human trial study that performed VML treatment on 5 
patients using a porcine urinary bladder derived ECM has recently been published18.  These 5 
patients all had lower limb skeletal muscle VML injury sites. The importance of this study was 
that 3 of the 5 patient’s involved experienced functional improvement at the injury site six 
months after the original surgery. All of these results however are still not enough evidence to 
completely eliminate the muscle flap option as the current treatment method for VML.  
 The second approach to treating VML with the hopes of regenerating new native skeletal 
muscle is engineering ECM (eECM) from skeletal muscle cells19. This technique of engineering 
an extracellular matrix is still fairly new. An in vivo study was performed within a rat animal 
model to observe the degradation time and inflammation response generated from the eECM. A 
VML site was not generated in this model but the eECM implant was placed within a surgically 
induced pouch within this model. By the first time point at 4th weeks after implantation, the 
eECM was still degrading and evidence suggested remodeling at the implant site. By the 12th 
week after implantation of the eECM, the implant was completely degraded and no evidence of 
chronic inflammation was observed. This suggests the eECM derived from skeletal muscle cells 




produced within our lab, more desirable traits based on human skeletal muscle ECM was 




The main objective of the present study was to characterize human skeletal muscle 
extracellular matrix (ECM). More specifically, characterize and understand the properties of 
human rectus femoris ECM and human supraspinatus ECM. Lastly, compare the two different 
human skeletal ECM locations along with comparing female ECM to male ECM.  
 
1.5 Key Chemical ECM characteristics: (Components)  
 
Extracellular matrix (ECM) is a group of cellular components that surround different 
tissues and organs to perform specific functions. ECM structure and composition is different 
based on the location of the tissue/organ it surrounds. Generally, ECM consists of collagen, 
glycosaminoglycans, proteoglycans, and glycoproteins. ECM has multiple functions that include: 
cell adhesion, cell proliferation, cell differentiation, cell structural support, and tissue 
regeneration. These functions are carried out by the different cellular components within the 
ECM.   
Collagen is the most abundant protein within the ECM. Different types of collagen have 
been identified and characterized within different types of ECM, however collagen I is the most 




but in smaller amounts. For example, type I, II, III20,21, IV, V-VIII22, and XI-XIII22 have all been 
identified within skeletal muscle ECM. Collagen is important for its structural and mechanical 
function due in part to the alignment of the proteins and the recruitment of cells to the ECM23. 
Collagen fibers form into many different types of collagen fibrils. Collagen has a triple helix that 
is composed of three helical polypeptides. The presence of collagen within materials is usually 
identified through the presence of hydroxy-proline. Hydroxy-proline is one of the amino acids 
that makes up the polypeptides alpha helices. Hydroxy-proline makes up 13.5%24 of collagen, 
making it a predominant identifier when looking for the presence of collagen. Homologous 
regions within the triple helix of individual collagen types are responsible for the formation of 
fibrils; therefore collagen is one of the main components that provides structural support to 
ECM25. Certain collagen types have been shown to help with cell attachment. Collagen type I 
has been proven to enhance cell attachment, proving collagen type I promotes cells to adhere to 
the ECM26.  When exposed to different cell types, collagen types I and II have been shown to 
induce differentiation of certain cell populations, maturation of cell populations, and maintain 
overall survival of cell populations27. The results of different interactions with collagen types I 
and II indicate ECM has the potential to stimulate differentiation, proliferation, and survival of 
multiple cell types.  
Glycosaminoglycans (GAG) and proteoglycans (PG) components serve cellular and 
structural functions within the ECM. Proteoglycans are proteins that consist of a “core protein” 
with one or more covalent glycosaminoglycan side chains28. Glycosaminoglycans are very large 
and do not fold. This results in the ECM having a large surface area around the corresponding 
tissues. In general, proteoglycans are negatively charged causing an osmotic imbalance resulting 




against compressive forces acting upon the ECM.  GAGs and proteoglycans also serve cellular 
functions within the ECM. The most common GAG side chains, chondroitin sulfate, dermatan 
sulfate, and heparan sulfate have all been identified within skeletal muscle ECM29,30. Decorin, a 
proteoglycan with either a chondroitin sulfate or dermatan sulfate GAG side chain, has been 
studied extensively21,31. Decorin has been proven to bind to collagen types I-IV within ECM 
indicating its role in helping the initiation of fibril formation of collagen fibers. Other dermatan 
sulfate and heparan sulfate proteoglycans have been shown to bind to fibronectin, another ECM 
component32,33. These interactions show how different cellular components of ECM interact with 
each other. Another class of proteoglycans, chondroitin sulfate, with a chondroitin sulfate GAG 
side chain, has been studied in regenerating skeletal muscle34. Chondroitin sulfate has been 
proven to be synthesized within regenerating skeletal muscle; however chondroitin sulfate has 
not been proven to inhibit or enhance the production of regenerating skeletal muscle. More 
studies on this particular PG with a chondroitin sulfate GAG side chain should be performed in 
order to conclude its role in the ECM.  
Cellular fibronectin and laminin are glycoproteins within ECM35. Fibronectin and 
laminin have been studied extensively on how they interact with cells when exposed to different 
conditions. Both fibronectin and laminin promote cell adhesion, indicating they can attract cells 
to attach to ECM26. Fibronectin36,37 and laminin37 have been shown to enhance cellular 
attachment of collagen type I and IV with other cell types in vitro.  Both glycoproteins also 
promote proliferation of cells38. This function of fibronectin and laminin indicates when cells 





1.6 Key Physical ECM characteristics: (Mechanics and Architecture)  
 
 
ECM has specific mechanical and architectural properties based on the original location 
of the muscle it originated from39. Since ECM properties mimic the properties of the original 
muscle, skeletal muscle ECM has a more distinct architecture than other ECM materials. The 
collagen fibers within skeletal muscle ECM are densely packed together to give the material its 
mechanical properties. The more aligned the collagen fibers, the stiffer the ECM material. The 
mechanical and architectural properties of ECM helps with the cellular functions ECM also 
possess40. Porosity is another architectural property skeletal ECM possesses. The pores are used 
as a pathway for cells to enter and leave the ECM. Different cells also use the pores to proliferate 
and differentiate while in the ECM. Usually ECM material with high mechanical properties and 
a distinguished architecture are used as biologic scaffolds when these parameters are needed. 
Some ECM materials do not require specific alignment or mechanical properties. For example, 
the use of cardiac derived ECM is being used as an injectable gel to help promote cardiac muscle 
regeneration41. The ECM material being used in this case does not require mechanical or 
architectural characteristics. The function of the ECM should be taken into consideration when 




Since ECM has many desirable qualities for regenerating muscle/self-repair, ways of 




through decellularization of tissues/organs. Decellularization is the removal of cellular 
components from any desired tissue/organ, and decellularization of tissue/organs can be 
completed using different techniques. The two most common techniques used for 
decellularization is a perfusion method or a constant agitation method. The main difference 
between the perfusion method and the constant agitation method is the mechanism each method 
uses to decellularize materials42. Perfusion decellularization uses a convective mechanism while 
agitation decellularization uses a diffusion-based mechanism.  Convective flow is described as a 
moving liquid over a solid surface as a result of a pressure differential. The decellularization 
agent is the “moving liquid” and the material is the “solid surface” in this scenario. Diffusion 
works differently than convection by moving particles from a high concentration to a low 
concentration as a result of a concentration gradient.  
The perfusion decellularization method has been performed on different types of whole 
organs with extensive vasculature: ferret liver, pig kidney, pig pancreas, pig intestines43, rat 
hearts44, and rat lung45. Perfusion decellularization involves pumping a detergent through the 
vasculature of the organ continuously until the material is completely decellularized. A specific 
example of perfusion decellularization is with the rat heart. Typically, the perfusion of the 
decellularization agent starts in the ascending aorta allowing the agent to continuously flow 
through all of the corresponding arteries and veins to eventually flow out of the left ventricle44.  
A tissue/organ is considered to be “completely decellularized” when DNA/RNA and intracellular 
structural proteins are removed44. Visual changes will occur when a tissue/organ has been 
decellularized. The material will gradually turn from a deep red color to a pure yellowish/ white 
color indicating blood and cellular components (nuclei and cellular actin) are perfusing out and 




original architecture, and the decellularization time is greatly reduced when compared to the 
agitation method.  
The alternative method for decellularization is constant agitation or constant “stirring”.  
This method is performed within a semi-large container that includes a detergent and the desired 
material. The container can either be placed on a rocker plate with slight agitation, or the 
container can be placed on a stir plate and the container would have a stir bar to provide constant 
agitation. Decellularization using the constant agitation/stirring method has been used in many 
tissues and organs: human adipose tissue from human lipoaspirate46, porcine skeletal and cardiac 
tissue from intercostal muscles22, canine quadriceps and hamstrings47, porcine dermis and 
urinary bladder48, porcine brain and spinal cord49, and porcine myocardial ventricular tissue50. 
This method also decellularizes material well, however this method requires more time than the 
perfusion method. The amount of time agitation decellularization takes is dependent on the 
thickness and density of the tissue that’s being decellularized. Depending on how much agitation 
is applied to the material during decellularization will determine how much of the original 
architecture is left intact. Both systems require a detergent, but any detergent can be used for 
both systems.  
Two common detergents used for decellularization are Triton X-100 and sodium dodecyl 
sulfate (SDS).  Both detergents have been compared to each other in previous studies to see 
which detergent is the most effective at decellularizing material. Triton X-100 is a non-ionic 
detergent that causes very mild effects on tissues when it is used for decellularization51. Non-
ionic detergents use lipid-lipid interactions or lipid-protein interactions to remove cellular 
components from tissue/organs. Non-ionic detergents do not disrupt protein-protein interactions 




material. SDS is an ionic detergent that is also commonly used for different decellularization 
processes51. Ionic detergents disrupt protein-protein interactions when they are used for 
decellularization, which can disrupt the original architecture of the tissue/organ. Triton X-100 
has been shown to partially remove cellular components within tissue/organs when compared to 
SDS44. SDS and Triton X-100 were both used to decellularize rat hearts, and the resulting ECM 
was analyzed to compare the effects both detergents had on the material44. Individual hearts were 
either decellularized with Triton X-100 or SDS using the perfusion method for 12 consecutive 
hours. After the allotted time, the SDS perfused heart was completely decellularized when 
compared to the Triton X-100 perfused heart. Visual observation of the hearts showed the SDS 
perfused heart was completely clear/white, while the Triton X-100 perfused heart was still 
pinkish/clear. These observations indicate complete removal of cells from the SDS perfused 
heart compared to the Triton X-100 perfused heart. Also, immunohistochemical analysis was 
performed on the two separate hearts. These results indicated the SDS perfused heart contained 
no nuclei or contractile elements. However, the Triton X-100 perfused hearts did contain small 
amounts of nuclei and contractile elements. This comparison proves SDS is more efficient than 
Triton X-100 for decellularization methods. Triton X-100 has also been compared to SDS to 
evaluate which detergent removes native collagen and GAG components within decellularized 
porcine anterior cruciate ligament52. The agitation decellularization method was used to compare 
the detergents. Both Triton X-100 and SDS removed native collagen and GAG components 
within the ligament equally. These observations indicate both detergents are capable of removing 
important ECM components from native tissue/organs.  
In addition to detergents, decellularization methods can also include buffers, 




into a detergent solution enhances the decellularization process. EDTA is a chelating agent51 that 
can cause cell lysis by binding to divalent cations that are present on cell adhesions to the ECM. 
Tris-HCL buffer is used to keep the solution containing the EDTA and detergent at an optimal 
pH as well as permeabilizing the outer membrane of the tissue/organ by interacting with 
lipopolysaccharides that are present on the membrane.  EDTA paired with Tris-HCL is not 
known to remove cellular components from the tissue/organ, it simply opens the membrane in 
order for the detergent to remove the components. A DNAse/RNAse buffer along with a DNAse 
I and a RNAse-A solution is used on the decellularized tissue/organ to completely remove any 
remaining DNA/RNA the detergent could have left behind during the decellularization process. 
A host could experience an immune response if there is any remaining DNA/RNA within the 
material that is implanted. A typical DNAse/RNAse buffer consists of Tris-HCL, MgCl2, NaCl, 
and CaCl2
53. The Tris-HCL keeps the buffer solution at the correct pH for DNA extraction (pH = 
7.4), as well as permeabilizes the membrane of the tissue/organ. CaCl2 acts as an activator of 
DNAse I, and MgCl2 enhances the effect of DNAse I on DNA. The activity of DNAse I is 
optimized in the presence of both MgCl2 and CaCl2
53. DNAse I cleaves each strand of DNA 
independently in the presence of MgCl2, and the site of cleavage is random. Unlike DNA I, 
RNAse-A does not require any cofactors for its activity, but RNAse-A does require NaCl to 
activate it. RNAse-A removes RNA that is not specifically bound within the tissue/organ. The 
addition of these agents helps remove any leftover cellular debris that may be left at the end of 
the decellularization process.  
By understanding the general functions of regular skeletal muscle and how it becomes 
traumatically injured as well as the current treatment methods for these injuries, the limiting 




extracellular matrix and understanding these characteristics, exploration of worthwhile 
alternatives to help improve current methods in volumetric muscle loss is possible.  
 
2. Materials and Methods 
 
2.1 Overview of experimental design 
 
Whole human rectus femoris (RF) and supraspinatus (SS) skeletal muscle samples (n = 
8/muscle type, 4 male and 4 female) were procured from a commercial tissue donation center 
(Science Care, Phoenix, AZ). Skeletal muscle samples were decellularized using a Tris-HCL, 
SDS solution and the resulting ECM biomaterial was thoroughly characterized to determine 
several key physical and chemical properties. Characterization tests included: 
1. ECM yield  (g ECM / g whole muscle) 
2. Collagen content (% dry weight),  
3. Glycosaminoglycan (GAG) content (% wet weight) 
4. Modulus of elasticity (kPa) 
5. Porosity (%) 
6. Network Alignment (degrees) 
7. Degradation rate (% volume loss / week) 
Whole and decellularized skeletal muscle sample architecture, surface appearance and 




of muscle harvest location (upper versus lower limb) and gender (male versus female) on each of 




Upon arrival, the RF and SS muscles were stored at -80°C. In preparation for 
decellularization, frozen whole muscle samples were thawed, cleaned of any residual fat and 
tendon, weighed, imaged, sectioned into strips or plugs, and batch decellularized following a 
published protocol.  Samples were soaked in 1% sodium dodecyl sulphate (SDS) with 1% EDTA 
in Tris-HCL buffer (pH 8.0) for approximately two weeks at room temperature using gentle 
agitation and multiple decellularization solution exchanges.  To remove nuclear remnants, 
samples were incubated for 12 hours at 4°C in a reaction buffer containing 1 kU/ml 
DNAse/RNAse. Samples were rinsed in PBS, (pH 7.4) for approximately 48 hours (4C) to 
remove any residual decellularization solutions. ECM yield for each muscle sample (n = 8 / 
muscle type, 4 male and 4 female) was calculated as the ratio of decellularized sample weight (g) 
to pre-decellularization whole muscle sample weight (g). Once decellularized, the hydrated 




Representative whole and decellularized skeletal muscle samples were sectioned with the 




paraformaldehyde, sectioned to the thickness of 15um and mounted on microscopic slides. 
Mounted sections were permeabilized with 0.1% Triton X-100 and blocked with 4% goat serum. 
Slides were immune-reacted for the presence of collagen type I (Sigma-Aldrich, 500:1), 
chondroitin sulphate proteoglycans (Sigma-Aldrich, dilution 500:1), and cytoskeletal actin, 
(Invitrogen, 50:1 dilution), followed by incubation in the appropriate fluorescently labeled 
secondary antibodies (Alexa 488 and 594, Invitrogen, 500:1). Sections were counter stained with 
the nuclear dye DAPI (Invitrogen, Grand Island, NY 1:20 dilution) and then microscopically 
imaged. Additionally, representative whole and decellularized muscle samples were lyophilized, 
sputter coated with platinum, and imaged with the aid of a scanning electron microscope.  
 
2.4 Porosity and Orientation 
 
Decellularized RF and SS samples were incubated in 10% formalin overnight at 4°C, 
paraffin embedded and sectioned in either the transverse (across muscle fibers) or longitudinal 
(along muscle fibers) direction with the aid of a microtome (5um). Sections were mounted on 
microscopic slides, stained with hematoxylin and eosin (H&E), and microscopically imaged 
(100X). Two representative images from each sample (n = 8 / muscle type, 4 male and 4 female) 
were used to measure porosity (% open space), and ECM network alignment (average oriented 
angle) using image analysis software (ImageJ) and guided by published techniques54,55. Porosity 
and alignment were measured from transverse and longitudinally sectioned samples respectively. 
The direction of muscle contraction (long axis of the RF and SS muscles) was selected to 





2.5 Biochemical Assessment 
 
Decellularized RF and SS sample collagen content (% dry weight) was estimated from 
hydroxy-proline concentration. Hydroxy-proline concentration was determined from extracted 
samples (n = 8 / muscle type, 4 male and 4 female) using a published technique56.  Briefly, 
extracted samples were digested in a 6N HCL solution (20 hrs at 115°C) and then neutralized 
with sodium hydroxide. Digested samples were mixed with a chloramine T solution (1:2) and 
incubated at room temperature for 20 minutes. A dimethyl-aminobenzaldehyde assay solution 
was added (1:2) and the mixture was incubated at 65°C for 25 minutes. During this time a red 
chromophore develops. Chromophore intensity indicates hydroxy-proline concentration. Sample 
absorbance was read at 570 nm using a microplate reader. RF and SS values were compared 
against a standard curve, and collagen concentrations were calculated. Samples were tested in 
triplicate. 
Glycosaminoglycan concentrations of human RF and SS ECM samples (n = 8 / muscle 
type, 4 male and 4 female)  were determined with the Blyscan Sulfated Glycosaminoglycan 
Assay Kit (Biocolor Ltd., Carrickfergus, Co Antrium, United Kingdom). Briefly, samples were 
digested using a papain extraction reagent method. Samples were digested at a concentration of 
30-40 mg (wet weight) per 1.5 ml of papain reagent at 65°C for 3 hours. Digested samples and 
standards were treated with Blyscan dye reagent then treated with dissociation reagent. Samples 






2.6 Mechanical Testing  
 
In preparation for mechanical testing, RF and SS muscle sample (n = 8/ muscle type; 4 
male and 4 female) were thawed at room temperature and sectioned into 3cm X 0.5cm strips 
aligned in the direction of muscle contraction. Uniaxial tensile testing was accomplished with the 
aid of a computer controlled material testing system (Model, Instron, Norwood, MA) 
incorporating a 10N load cell. Manufacturer software (Bluehill® Lite, Instron, Norwood, MA) 
was used to control strain rate and record force/elongation data. The long axis of hydrated 
samples (PBS) was aligned in the direction of loading and secured at each end using hand 
tightened serrated grips. A gauge length of 2 cm was used for all samples. Prior to tensile testing, 
samples were pre-conditioned using 5 cycles of 10% strain to establish a uniform loading history 
for all samples. Immediately following pre-conditioning, each sample was loaded to failure at a 
quasi-static strain rate of 10 mm/min. Raw data were collected at a sampling rate of 10Hz. For 
each tissue sample, engineering stress versus strain curves were generated from load and 
elongation data. From these curves, the tangent modulus was calculated as the slope of a linear 
curve fit to the stress-strain region extending from the end of the toe-in region (5%) to 20% 
strain. Secant moduli, at 10% and 20% strain were also calculated. 
 
2.7 In-vivo Degradation  
 
In-vivo degradation was examined using a dorsal subcutaneous implant site in a mouse 
model. In-vivo degradation was assayed at short-term (4 weeks) and mid-term (8 weeks) time 




time points tested. All surgical procedures were performed in accordance with protocols 
approved by the University of Arkansas Institutional Animal Care and Use Committee.  
Anesthesia was induced via IP injection of a ketamine/xylazine cocktail. The subcutaneous 
implant site was surgically exposed through a 2 cm left-right incision placed 2 finger widths 
caudal to the scapulae. A subcutaneous pouch was created in each animal by blunt dissection. A 
single ECM disk (approximate size 9.5mm x 3mm) prepared from decellularized RF muscle was 
implanted into each pouch (approximate implant size). Incisions were closed using surgical 
adhesive (VetBond, 3M).  Following surgery all animals were housed in the University of 
Arkansas Central Laboratory Animal Facility. At the prescribed time-points (4 and 8 weeks) all 
were euthanized via inhalation of carbon dioxide. The implant site with surrounding soft tissue 
was harvested and imaged.  From the images, implant diameter was measured and used as a 
metric of ECM degradation.  
 
2.8 Statistical Analysis 
 
All data is presented as the mean ± the standard error of the mean, except for the ages and 
weights of each sample, which is presented as mean ± standard deviation. The yield, collagen 
content, GAG content, elastic modulus, elastic modulus at 10% strain, porosity, and oriented 
angle were all analyzed with a two-way analysis of variance (ANOVA) and a student two tailed 
t-test assuming equal variance. The half – life was recorded for the degradation of the ECM 
pellet. Significance difference was reported as P < 0.05 for all data. All of the ANOVA’s were 
performed using JMP software (JMP Statistical Discovery from SAS, Cary, NC), and all student 







The average age of all of the samples (RF and SS) was recorded at 71.32 ± 19.59 years 
old, while the average age of the RF samples and the SS samples were 70.0 ± 22.14, and 65.8 ± 
22.90 years old, respectively (Table 1). The ages of RF samples ranged from lowest to highest, 
24 (male) – 98 (female), while the SS samples ranged 24 (male) – 95 (male). The full RF and SS 
muscles were visually inspected before the decellularization process began (Fig, 1, A, B). The 
weights of the rectus femoris and the supraspinatus varied greatly, which is to be expected since 
the RF is larger than the SS. There was a significant difference between the weights of the rectus 
femoris and supraspinatus, but no significant difference was observed for the ages of the 
different skeletal muscles.  The weight of the RF samples averaged 79.16 ± 30.48 grams, while 
the SS averaged 19.16 ± 5.48 grams (Fig. 1, C).  
The progress of decellularization for RF samples was visually recorded at Day 0, 5, and 
15 (Fig. 2, A) with Day 0 being before decellularization. Immunohistochemistry was also 
performed on non-decellularized and decellularized RF samples to observe the presence of nuclei 
and intercellular actin. The DAPI stain revealed multiple nuclei and the presence of actin in the 
non-decellularized sample, which is to be expected since those samples did not undergo any 
treatment (Fig. 2, B). The decellularized RF ECM did not show any nuclei present, the sample 
did however show some evidence of background staining for the actin, but actin was not 




Images were taken of RF ECM at a low magnification with a digital camera and high 
magnification with a SEM microscope. The low magnification image revealed how much 
material was left after decellularization as well as some indication of alignment (Fig. 3, A). The 
SEM image revealed a magnified look at the fibers within the ECM (Fig. 3, B). The fibers are all 
intertwined with each other with indication of alignment.  
The amount of material salvaged from both RF and SS samples after decellularization 
was closely related. The RF ECM samples (both male and female) has a slightly higher yield 
(21.44 ± 3.86%) than the SS ECM samples (both male and female), 19.10 ± 3.72% (Fig. 3, C). 
The female RF ECM samples (26.43 ± 6.34%) produced a slightly higher yield than the SS 
female ECM samples (21.22 ± 7.40%). The male RF ECM samples (16.44 ± 3.57%) and the 
male SS samples (16.98 ± 2.65%) produced similar amounts of ECM material.  
The presence of collagen within the RF ECM after decellularization was observed after 
immunofluorescence staining (Fig. 4, A). The collagen content of the RF ECM and the SS ECM 
was significantly different from each other with 2.27 ± 0.31% and 4.78 ± 1.05% (Fig. 4, B). The 
male and female samples within the RF ECM were similar to each other with 2.45 ± 0.57% and 
2.09 ± 0.38%. Both male and female samples within the SS ECM group were higher than the 
male and female samples in the RF ECM group. The female SS ECM was higher, 5.31 ± 1.99% 
than the male SS ECM 4.25 ± 0.22%.   
Glycosaminoglycans, more specifically CSPGs, were observed in the RF ECM following 
proper staining (Fig. 5, A). The total sulfated GAG content of the RF ECM was slightly higher 
than the total sulfated GAG content of SS ECM with 4.65 ± 0.43% and 3.94 ± 0.54% total 




were similar to the sulfated GAG content of the male samples with 4.46 ± 0.16% and 4.83 ± 
0.29% total weight. The female and the male SS ECM samples for the sulfated GAG content 
were closely related when compared to the RF ECM samples, with 3.02 ± 0.57% and 4.86 ± 
0.69% total weight. Male and Female groups for all of the muscle samples were significantly 
different for the sulfated GAG content.  
The average porosity for both RF ECM and SS ECM samples were closely related. A 
representation of the general porosity of each group (RF and SS ECM) is represented in (Fig. 6, 
A). The average porosity for the RF ECM samples as a whole was slightly higher than the SS 
ECM samples as a whole with 79.26 ± 5.36% and 73.65 ± 3.39% open space (Fig. 6, C). The 
female RF ECM samples averaged slightly lower than the male RF ECM samples, 75.25 ± 
10.91% and 83.27 ± 2.02% open space. There was no significant difference with the RF ECM 
female and male groups even though the male samples were slightly higher. The female and 
male SS ECM porosity samples were more closely related than the RF samples, with 71.92 ± 
5.58% and 75.38 ± 4.51% open space.     
A representation of both RF ECM and SS ECM fiber alignment is represented in (Fig. 6, 
B). The oriented angle indicated the overall network alignment for the skeletal ECM. The RF 
ECM oriented angle sample has a slightly smaller angle than the SS ECM sample with 10.64 ± 
1.66 degrees and 13.41 ± 2.46 degrees, respectively (Fig. 6, C). The female and male samples 
within the RF ECM sample group have a significant difference between them with 14.74 ± 0.71 
degrees and 7.57 ± 1.43 degrees. The female and male samples within the SS ECM sample group 




 A representative stress/strain curve for the modulus of elasticity for both human RF ECM 
and SS ECM is shown in Figure 7 with the red line representing the RF ECM and the green line 
representing the SS ECM (Fig. 7, A). The graph shows the RF ECM for both male and female 
have a higher overall modulus of elasticity (kPa) than both male and female groups for the SS 
ECM. The overall modulus of elasticity for the RF ECM was recorded at 320 ± 109 kPa, while 
the overall modulus of elasticity for the SS ECM was recorded at 161 ± 43 kPa. The male RF 
ECM group had a slightly lower overall modulus of elasticity than the female RF ECM group 
with 268 ± 95 kPa and 372 ± 211 kPa, respectively. The male SS ECM group also had a lower 
overall modulus of elasticity than the female SS ECM with 92 ± 33 kPa and 246 ± 69 kPa (Fig. 
7, B). The modulus of elasticity at 10% strain also varied within all of the ECM groups. For 
example, the RF ECM modulus of elasticity at 10% strain was higher than the SS ECM with 355 
± 140 kPa and 168 ± 45 kPa. The male RF ECM modulus of elasticity at 10% strain was 271 ± 
98 kPa, while the female RF ECM modulus of elasticity at 10% strain was 439 ± 276 kPa. The 
last comparison for the modulus of elasticity at 10% strain is between the male and female SS 
ECM groups. The modulus of elasticity at 10% strain for the male SS ECM group was 120 ± 55 
kPa and the modulus of the elasticity at 10% strain for the female SS ECM group was 227 ± 69 
kPa (Fig, 7, C). Even though all the groups for both the overall modulus of elasticity and the 
modulus of elasticity at 10% strain were different for all the characterization parameters, no 
significant difference was reported.  
The average diameter for the degradation of the RF ECM pellets were recorded at 3 
different time points (0, 4 and 8 weeks). First, the image within Figure 8 represents the initial 
size of the RF ECM pellet at the time of implantation at week 0 (Fig. 8, A). Within the image, 




representation of the initial size/diameter of the RF ECM pellet in comparison to standard 
surgical tweezers (Fig. 8, A, inset). The initial diameter of the RF ECM pellet was recorded at 
8.94 ± 0.23 mm. The 4 week diameter of the RF ECM pellet was recorded at 4.49 ± 0.44 mm, 
and the 8 week diameter of the RF ECM pellet was recorded at 2.10 ± 1.02 mm. The half-life for 
the degradation of the RF ECM pellet in vivo is 3.83 weeks. No statistical analysis was 




A method for preparation of decellularized human RF and SS ECM samples and 
characterization is described in the present study. The decellularization protocol used throughout 
this study successfully removed cellular components, therefore ensuring the material being 
characterized was skeletal muscle extracellular matrix. Even though the two skeletal muscle 
groups were taken from two separate parts of the human body, the results for both skeletal 
muscle ECM types are closely related. Within certain characterization tests, the male and female 
groups within the same muscle ECM type showed significantly different results even though the 
two different muscle types did not show significant differences. 
Many different techniques are used to decellularize different types of muscle. Evidence 
provided by our immunofluorescence staining for actin and nuclei, and by visually observing a 
change in color of the skeletal muscle indicated our decellularization protocol was a success. 
Visualization is a basic yet effective method to use when decellularizing muscle. If the initial red 




an improper decellularization protocol. For example, an improper protocol could include: 
significantly low detergent concentrations used within the protocol, the decellularization 
technique is insufficient, or the possibility of expired detergents being used.  
Visualization of gradual decellularization has been observed in different muscle types44. 
For example, a complete rat heart was confirmed to be decellularized through visual observation. 
Multiple detergents were compared to each other by a perfusion decellularization method. 
Triton-X-100 and 1% SDS were compared based on their effectiveness in removing cellular 
components. The rat heart that underwent Triton-X-100 decellularization was still a dull pinkish 
color after 12 hours of decellularization, while the rat heart decellularized with 1% SDS for the 
same amount of time was a white/clearish color. This color change indicates removal of cellular 
components.  
Another method to verify decellularization is immunofluorescence staining using DAPI 
to identify nuclei and phalloidin to identify intercellular actin. These stains are usually performed 
on native muscle being used for decellularization and finished ECM. Complete decellularization 
within the rat heart was also verified by these staining techniques44. Since the decellularization 
method was observed through visual observations for the heart treated with 1% SDS, the SDS 
perfused rat heart was compared with native rat cardiac muscle. The results of the 
immunofluorescence staining also verified that the best detergent to completely remove cellular 
debris is SDS. Phalloidin and DAPI stains revealed no presence of actin or nuclei, while the 
native cardiac tissue was full of nuclei and actin. Our results also indicated 1% SDS along with 
buffer solutions and chelating agents removed cellular components. The immunofluorescence 
stain for nuclei and actin within native skeletal muscle and within ECM from skeletal muscle 




decellularization study. By comparing our decellularization results with other studies that used 
the same visual observation and immunofluorescence technique, our decellularization method 
was a successful protocol for decellularization of skeletal muscle.  
Another method to verify decellularization of muscle is to quantify DNA by using DNA 
assays, more specifically the PicoGreen assay. This assay can detect DNA concentrations that 
are as little as 25 pg of DNA/ml of dsDNA reagent. One group has verified their 
decellularization method on canine quadriceps by using this particular assay47. This group 
considered their material to be decellularized when the DNA content was less than 50 ng 
dsDNA/mg ECM (dry weight). The DNA levels within the canine quadriceps ECM was 7.42 ng 
DNA/mg ECM. DNA assays, immunofluorescence staining, and visual inspection are all 
accepted techniques to quantify the decellularization of muscles within current literature.  
When choosing a muscle type for decellularization to use as a specific treatment method, 
yield of ECM material and original location are important factors to consider. The yield results 
found within this study indicate that location and gender do not have an effect on yield of 
skeletal ECM. Both skeletal muscle types yielded about the same percentage of ECM. Based on 
the weights of each muscle type, the larger muscle would be expected to yield more ECM than 
the smaller muscle. Our group found that the size of the skeletal muscle is not a factor when 
measuring the yield of ECM from these muscles.  
Different ECMs are used as treatment methods for various injuries or conditions. Some 
ECMs are chosen as treatment methods based on their original architecture and their original 
muscle location, however, some ECMs are chosen as treatment methods with no regard to the 




to use as a treatment method for a volumetric muscle loss injury in the tibialis anterior region of 
a rat animal model15. The decellularized tibialis anterior muscle was chosen as the ECM used for 
this injury based on the original location of the skeletal muscle. Architecture of the 
decellularized tibialis anterior muscle is quite similar to the native architecture of the tibialis 
anteior muscle. This specific characteristic could promote healing within the volumetric muscle 
loss injury that was created. Other groups do not consider the original location of ECM when 
treating volumetric muscle loss sites. A different group created a volumetric muscle loss injury 
within a canine animal model57. This group used small intestinal submucosa ECM as the 
treatment method for the treatment of a volumetric muscle loss injury created in an Achilles 
tendon. The architecture and original location of the ECM did not play a role in the decision to 
use this material to treat the Achilles tendon injury. The results from this study did show 
regeneration of the Achilles tendon when the small intestinal submucosa ECM was used as the 
treatment method. Based on these current studies, original location and architecture is sometimes 
considered when choosing ECM as a treatment method.  
If skeletal ECM from this study was used as a treatment method and the original location 
and architecture was not a factor when choosing the material then the RF ECM should be 
chosen. The RF ECM and the SS ECM yield the same amount of ECM, but the native RF 
produces a larger quantity of skeletal ECM based on the original size of the muscle. Therefore, 
choosing the larger muscle that weighs more would be the logical choice. If the original 
architecture and location needed to be considered then the quantity of ECM would not play a role 
in the selection of skeletal ECM.  
The skeletal muscle ECM yield in this study is comparable with different ECM yields 




and human pericardium ECM yield has been studied. The decellularization method used for that 
study is similar to the method used within this study. Briefly, the ionic reagent SDS and DI 
rinses were used to decellularize this tissue. The yield collected for porcine pericardium 
measured 20 mg of dry weight ECM, and the human pericardium yielded 17- 40 mg of dry 
weight ECM58. Original size of the tissue pieces before decellularize ranged between 2 to 4 cm2. 
This data is presented as mg of ECM recovered, while the skeletal muscle ECM yield within this 
study is presented as ECM yield from percent of original weight of each piece. The porcine and 
human pericardium ECM and the RF ECM and SS ECM cannot be directly compared based on 
how the data is presented. However, being able to compare different decellularized ECM tissue 
type yield amounts from human or different species provides insight into how much material 
different types of muscle can yield.  
By viewing the decellularized skeletal muscle ECM with SEM technology, our group 
was able to view a 3-D image of the RF ECM that identified the porosity of the skeletal ECM. 
The 3-D image identified individual collagen fibers along with individual pores within the 
skeletal muscle ECM. The human RF ECM can be compared to different types of ECM. For 
example, dog quadriceps of both native and decellularized ECM has been characterized47. For 
comparisons between the human RF ECM within this study and the dog skeletal muscle ECM 
within the Badylak study, SEM images of both the native and ECM dog skeletal muscle was 
observed at 500x. The 500x SEM image of native dog muscle was very structured compared to 
the decellularized dog skeletal muscle ECM and the human RF ECM. The native dog muscle had 
more alignment and more cellular components within its structure. The location of the collagen 
fibers within the native dog skeletal muscle were confirmed based on how the cellular 




ECM and the human RF ECM were similar in that they both showed the presence of collagen 
fibers without cellular components attached to them. Another SEM comparison can be made 
with the human RF ECM and with rat heart ECM44. The rat heart ECM did lose some of the 
original architecture after the decellularization process, however the rat ECM still had evidence 
of collagen fibers. These same conclusions can be stated about the human RF ECM when 
comparing it to rat heart ECM. Comparison of the human RF ECM with two types of muscles 
(quadriceps and heart) from two different species (dog and rat) provides evidence that the human 
RF ECM has similarities to other types of ECMs.  
Collagen and GAGs are a few of the main components that make up ECM. These 
components contribute to the different functions ECM materials are capable of performing. This 
makes collagen and GAG assays a desirable method in characterizing decellularized 
tissues/organs.  By knowing which skeletal muscle ECM yields the most collagen and GAG 
content then the use of this skeletal ECM material could be evaluated as a specific treatment 
method, if needed.  
The two different skeletal muscle locations have a significant effect on the collagen 
content of their ECM. The SS ECM collagen content doubled the RF ECM content, showing a 
significant difference. Since human skeletal muscle ECM has not been characterized before, 
there are no results to directly compare to the results found in this study.  Some conclusions can 
be drawn from the collagen content data. Since location of the two skeletal muscles showed a 
significant difference, certain factors could potentially affect the collagen levels from the two 
different ECMs. For example, extreme exercise has been shown to make collagen levels 
fluctuate within the muscle that is primarily being exercised. One studied showed how the 




substantial amount of time fluctuate between high levels of collagen and normal levels of 
collagen59. Another study showed similar results as the one just mentioned, however instead of 
measuring the fluctuation of collagen levels in the quadriceps this study measured fluctuation of 
collagen levels in the supraspinatus muscle of rats60. Aging has been reviewed as a factor that 
can also affect collagen levels in skeletal muscle. A previous study showed how collagen levels 
within lower limb skeletal muscle experiences multiple trends in aging rats61. A common trend 
observed within this study was the dramatic increase in collagen levels within the extensor 
digitorum longus of rats at age (measured in days) 21 to age 86. Then the collagen levels 
decreased slightly from age 86 to age 188. From age 188 to age 299 collagen levels decreased 
dramatically compared to age 86. This suggests that age can potentially play a very important 
role on collagen content. By looking at some of these factors that can contribute to collagen 
levels and knowing that an upper skeletal ECM compared to a lower skeletal ECM has a higher 
collagen content, then making a decision of what type of ECM would be beneficial when using 
this ECM as a treatment method.  
The gender did not have a significant effect on the collagen content within the two 
different skeletal muscle ECM groups (RF ECM and SS ECM); however the gender did have a 
significant effect on the GAG content within skeletal muscle ECM. GAGs play important roles 
within the ECM, and by knowing percent total weight of GAG in two different types of ECMs 
provides insight into which material would be better used as a treatment method. By knowing 
male and female ECM have different levels of GAGs, then using the material that contains more 
GAG would be more efficient when using ECM as a treatment method. More GAGs can provide 
the ECM with more desirable functions. For example, GAGs have been shown to interact with 




also been shown to help with certain mechanical functions, by providing a “cushion” type 
response to the ECM against compression forces28. It is possible that the male skeletal ECM 
could provide more desirable functions as a treatment method since the group had a higher GAG 
content that the female group, but more testing would need to be conducted. Unlike quantitative 
measurements of collagen for specific treatments, the measurement of glycosaminoglycans are 
usually performed as an indication of how many GAGs are in ECM.  
The collagen and GAG content from human RF ECM can be compared with other 
species ECMs collagen and GAG content.  By comparing quadriceps ECM collagen and GAG 
levels from different species to the human RF ECM collagen and GAG levels, helps to verify 
which species quadriceps ECM yields the most collagen and GAG levels. GAG levels within 
native dog quadriceps and dog quadriceps ECM have been evaluated within current literature47. 
Both the native dog quadriceps and ECM were much lower than the human RF ECM GAG 
content found within this study with the native dog quadriceps GAG content being 3.02 ug/mg 
dry weight and the dog ECM being 0.61 ug/mg dry weight. This comparison shows how 
different species affect the GAG content of the same type of muscle ECM. The collagen levels of 
dog ECM was not measured within that study. Another quadriceps ECM study was performed on 
rats that did measure collagen content, but not GAG content62. The collagen content found within 
rat quadriceps ECM was higher than the collagen content found within the human RF ECM with 
the rat quadriceps ECM being 72% (assuming total weight). A possible explanation for this 
discovery of higher levels of collagen in rat ECM compared to human ECM could go back to the 
quality and the age of muscle used within this study. The rats used in the Van Dyke study were 
sacrificed at 4 to 7 months for characterization. Based on a study that compared rat ages to 




20’s63. This comparison of rat skeletal ECM to the human RF ECM makes sense. Having an idea 
of which species yields the most collagen and GAG contents definitely helps when discovering 
new treatment methods based on these different species skeletal muscle ECM types.  
Now the human RF ECM and SS ECM can be compared to different decellularized tissue 
ECMs within different species. The first comparison is between rat lung ECM and the human 
skeletal ECM. This is a valuable comparison since some ECMs are being used as different 
treatment methods in multiple areas. One study characterized SDS-decellularized rat lung 
ECM45. Lung ECM is a semi-new ECM material that is being characterized within tissue 
engineering studies. The collagen content of rat lung ECM was higher than both the human RF 
ECM and SS ECM with the collagen content of rat lung ECM being 787 ug/whole lung, while 
the GAG content was similar for both the rat lung ECM and the human skeletal muscle ECM 
with the lung ECM being 20 ug/whole lung.  
Different muscle types (i.e. skeletal verses smooth) can yield different amounts of 
cellular components when compared to each other. Porcine ECM is very well studied within 
tissue engineering. For example, porcine heart, dermis, bone anterior cruciate ligament (ACL), 
brain and spinal cord ECM have all been studied recently. Decellularized porcine heart yields 
more GAG levels than both human skeletal muscle ECMs with the porcine heart ECM being 125 
ug GAG/mg dry ECM58. Collagen was shown to remain in the porcine cardiac ECM after 
decellularization, however the overall collagen content has yet to be studied. Another porcine 
ECM that has been characterized is the dermis ECM. The porcine dermis ECM yields much 
lower collagen and GAG amounts when compared to the human RF ECM and SS ECM with the 
collagen levels being 0.85 mg collagen/mg ECM and the GAG levels being 1.1 ug GAG/mg 




ECMs, the GAG levels for both the brain and spinal cord ECM are lower than the human skeletal 
muscle ECMs49. The porcine brain ECM yields 5 ug GAG/mg dry weight and the spinal cord 
ECM yields 1.3 ug GAG/mg dry weight. However, the collagen content for the spinal cord ECM 
and brain ECM have much higher levels of collagen than the human skeletal muscles49. The 
brain ECM yields 538 ug collagen/mg dry weight and the spinal cord ECM yields 703 ug 
collagen/mg dry weight. The last comparison between the human skeletal muscle ECM and 
porcine is the bone ACL ECM52.  The GAG content of the porcine ACL ECM was much lower 
than the human RF ECM and SS ECM with the ACL ECM being 0.07% dry weight, while the 
collagen content of the ACL ECM was higher than the human skeletal ECM with the ACL ECM 
being 86% dry weight.  
The next comparison is between human pericardium ECM and human skeletal ECM. The 
human pericardium ECM had a higher level of GAGs when compared to both the RF ECM and 
SS ECM with the human pericardium ECM being 137 ug GAG/mg dry ECM58. The collagen 
content for the human pericardium ECM was not measured within that study. When looking at 
all of these different comparisons to human skeletal muscle ECM, one should keep in mind that 
every muscle type is different, especially if they are from a different species besides human. By 
knowing all of these comparisons between different ECMs, gives someone a rough idea of what 
collagen and GAG levels should be in ECM material.  
The last comparison of collagen and GAG levels is between the human SS ECM and 
commercial ECM used in industry as a treatment method for rotator cuff repair64. Within that 
study, five commercially obtained soft tissue repair ECM materials were characterized. These 
commercial products are derived from multiple areas: porcine (small intestine submucosa), 




undergo some form of removal of cellular components before they are distributed. The collagen 
content and the GAG content of all of the commercial ECM material used for rotator cuff repair 
were lower than the collagen and GAG content of the human supraspinatus ECM found within 
this study. Based on this comparison, human supraspinatus ECM could potentially be used as a 
treatment method for rotator cuff repair. A direct characterization comparison between the 
human SS ECM and these commercial ECM products would have to be performed before further 
investigation.  
When engineering bioartificial scaffolds, keeping the original architecture and porosity of 
the desired tissue/organ is preferred. The decellularization protocol used within this study kept 
the original architecture and porosity intact for both the human RF ECM and SS ECM even 
though SDS has been known to affect these parameters in some cases51. The oriented angle 
measured within each group was an indication that skeletal muscle has an organized network 
alignment. The porosity values measured within this study were similar for all groups. The 
location and gender of skeletal muscle does not play a significant role in skeletal muscle ECM 
porosity measurements. The two different skeletal muscle ECM can have the same porosity 
measurement even though the two original skeletal muscles perform opposite functions. The 
oriented angle measured for the female RF ECM group and the male RF ECM group were 
significantly different. The female RF ECM doubled the oriented angle of the male RF ECM 
group indicating the female RF ECM samples are less aligned than male RF ECM samples. This 
could have a functional effect on the RF ECM. By knowing female RF ECM is less aligned than 
male RF ECM and if these ECM materials were used as a treatment method that required a more 




 If human RF ECM and SS ECM were used as a treatment method for muscle 
regeneration, for example, the original architecture of the muscles would be preferred if these 
skeletal ECM were implanted into their original locations. Currently, researchers are engineering 
devices to achieve some form of controllable architecture and porosity of skeletal muscle. A 
skeletal muscle tissue bioartificial scaffold with specific architecture and porosity has been 
shown to enhance cell viability in vitro40. Specific architecture and porosity of the engineered 
skeletal muscle tissue was achieved in this study by growing C2C12 rat myoblasts and primary 
rat skeletal myoblasts within either a fibrinogen or collagen type I hydrogel on top of a pre-
determined cell aligned and porosity controlled polydimethylsiloxane (PDMS) mold. The same 
cell/hydrogel mixture was grown on a PDMS mold that did not have any alignment or porosity to 
determine if the controllable parameters affected the cell growth of the rat myoblasts. The results 
from this study showed that the pre-determined pore size enhanced nutrient and oxygen transfer 
to the myoblasts, therefore improving cell viability when compared to the mold that did not have 
any structural parameters40. Also, cell differentiation and proliferation was shown to be more 
effective in the pre-determined mold. The cell alignment for the pre-determined mold was 
slightly higher than the oriented angle found within both the human RF ECM and SS ECM. The 
controlled porosity was similar to the porosity of both the human RF ECM and SS ECM with the 
controlled porosity of the PDMS mold being about 95% porous. These specific parameters for 
the architecture and the porosity can help predict how cells would grow on the RF ECM and SS 
ECM in vivo. Further research would need to be performed on skeletal ECM in order to 





 The stiffness of the human skeletal muscle ECM was evaluated by the overall modulus of 
elasticity and modulus of elasticity at 10% strain. There was no significant difference for the 
modulus of elasticity, however the lower limb skeletal muscle ECM had a higher modulus of 
elasticity than the upper limb skeletal muscle ECM indicating the RF ECM is stiffer than the SS 
ECM. Previous studies have shown, lower limb muscles within human cadavers experience load 
failure at around 10% strain, therefore the modulus of elasticity at 10% strain was evaluated65. 
Upper limb skeletal muscle tendons have been studied more than the upper limb skeletal muscles 
themselves. Based on current literature, humans and canine supraspinatus tendons share a load 
failure at about 8% strain64,66. Keeping the same parameters (modulus of elasticity at 10% strain) 
for both the RF ECM and the SS ECM during mechanical testing provided consistent results 
based on previous strain studies.  
Looking at collagen levels, GAG levels, and both modulus of elasticity’s for just the 
combined RF ECM and SS ECM, provides insight into the skeletal ECM based on the results 
found. The RF ECM was higher for both modulus of elasticity’s and GAG levels when compared 
to the SS ECM material, however the RF ECM has a lower collagen content than the SS ECM. 
This brings up the realization that collagen helps with mechanical loading within ECM, but 
GAGs also can contribute greatly to mechanical loading on ECM. Another observation can be 
made about the two different locations when looking at all three tests results. The collagen and 
collagen fibril formation was abundant within the SS ECM, however the strength of the 
components were weaker than the collagen present in the RF ECM. The strength of the ECM can 
also be traced back to the original functions of the RF and SS. The RF muscle goes through more 
strenuous work when compared to the SS muscle. For example, the RF muscle is used for 




rotator muscles to control the shoulder. By presenting all of this data about both types of skeletal 
muscle ECM, researchers will have a better understanding for the properties human skeletal 
muscle ECM. Another interesting observation from the modulus of elasticity data is that both 
female groups within the RF ECM and the SS ECM had a higher modulus of elasticity than both 
male ECM groups. This suggests that female ECM is stiffer than male ECM disregarding 
location of the skeletal ECM.  
 The modulus of elasticity at 10% strain for the SS ECM can be compared to commercial 
ECM used for the treatment of rotator cuff tears and canine infraspinatus tendons (part of the 
rotator cuff muscles), mentioned earlier in this study64. The method used for tensile testing of the 
commercial ECM products are similar to the tensile testing methods in this paper. The 
differences between the tensile testing methods is the load cell used for testing and the percent 
strain reached for the modulus of elasticity. The load cell used in this study was a 10N load cell, 
while the load cell used in the commercial ECM product study was either a 50 N or a 500 N load 
cell.  In our study, we reported the modulus of elasticity at 10% strain, while the commercial 
ECM products were measured at 8% strain. Based on visual observations for the modulus of 
elasticity at 8% strain for the commercial ECM products used in treatment methods for rotator 
cuff repair, the product derived from human dermis has a similar modulus of elasticity at 8% 
strain when compared to the SS ECM modulus of elasticity at 10% strain. All of the other 
commercial ECM products had a slightly higher modulus of elasticity at 8% strain when 
compared to the SS ECM modulus of elasticity at 10% strain. Based on this observation 
however, the modulus of elasticity at 10% strain for the SS ECM is just as stiff as a product used 




four commercial ECM products were all lower than the natural human skeletal ECM levels 
found in this study.  
 Degradation rate of the human skeletal ECM was evaluated within an in vivo mouse 
animal model. Based on the results, the diameter of the RF ECM pellet decreased in size at every 
time point (4 and 8 weeks). This degradation pattern was expected based on previous studies. 
Usually degradation studies are accompanied with repairing a defect in vivo, which was the case 
in a present study involving Achilles tendon regeneration in a canine animal model using 
decellularized small intestinal submucosa (SIS) ECM57. Within this study, degradation times 
were observed at 3 days, 1 week, 2 weeks, 3 weeks, and 8 weeks. The SIS ECM was implanted 
into a gap made in the Achilles tendon of female canines. By day 3 after implantation, the SIS 
ECM started to separate because host cells started to invade the foreign implant. This is the start 
of an inflammatory response. By week 1, mononuclear cells covered almost all of the ECM and 
new host ECM started to form. By week 2, the entire ECM implant was covered with 
mononuclear cells, and the original implant was 20% degraded when compared to the initial 
implant. By week 3, 60% of the original implant was degraded and new host ECM was observed. 
By week 8, the implant was completely degraded and new host ECM had taken over the defect 
site. The degradation time of the RF ECM in our mouse animal model also followed a decreasing 
trend like the one described above. By week 4 of the RF ECM degradation in the mice, 50% of 
the original RF ECM was degraded. Based on observations made from the previous study, 
inflammatory responses, more specifically, the recruitment of macrophages and neutrophils 
started to phagocytose the “foreign material” in the mice. By week 8 of the RF ECM 
degradation, 76% of the original RF ECM implant was degraded. Assuming the same 




in size of the RF ECM pellet was expected. Based on the degradation results and how the mice 
handled the implantation, human skeletal ECM could be used as a possible treatment method of 
some kind.  
Limitations to this study were the ages of the muscle donors and the quality of muscle.  
This could have affected the ECM that was used for the characterization tests. Different studies 
have identified the average age of donors in several countries. For example, a study conducted in 
New Zealand, South Africa, and Ireland reported the average age of individuals who donate their 
body to science are between 60-69 years old67. These findings correlate with the average age of 
donors used within this study, with the average age of muscle used being 71 years old.  
Since the donors were older, the quality of their skeletal muscle could have affected the 
characteristics of the ECM. For example, muscle fibers within young and older individuals have 
been characterized and compared to each other in current literature. Muscle fibers, specifically 
type I (slow-twitch) and type II (fast-twitch), found within skeletal muscle significantly 
decreases in size within individuals in their 50’s68. Muscle fiber size start to slowly decrease in 
number after an individual turns 25 years old, but when individuals become middle aged muscle 
fibers decrease in size faster than before. The size of skeletal muscle fibers indicate the overall 
skeletal muscle mass. This evidence indicates younger individuals have more muscle mass than 
individuals who are 50 years old and above. ECM surrounding these muscles start to shrink 
when muscle mass decreases in older individuals, causing less available ECM from older donors 
when compared to younger donors.  
Within a different study, quadriceps strength and cross sectional area have been 




groups, young individuals were 20-29 years old and older individuals were 71-81 years old. 
Within the male groups, young individuals were 21 to 28 years old and the older individuals 
were 70-79 years old. Within the young and old female groups, young individuals weighed 50 to 
73 kg, while the old weighed 43 to 88 kg. Within the young and old male groups, young 
individuals weighed 65 to 82 kg while the old individuals weighed 66 to 83 kg.  
Muscle strength in the old female group was shown to be 35% weaker than the young 
female group, and the cross sectional area of the quadriceps in the old female group was 33% 
less than the young female group. The difference in weight of the young and old females indicate 
that the old group was slightly heavier than the young group. This weight difference could have 
affected the quadriceps strength within the old group. This indicates both age and weight can 
play a role in muscle mass and strength, which affects the ECM.  
The muscle strength in the old male group was 39% weaker than the young male group. 
The old male group had 25% less muscle mass than the young male group even though the body 
weights of both male groups were practically the same. The male and female groups within these 
studies were not compared with each other. The data collected from the two male groups indicate 
that even if two sets of different groups have the same body weight, this does not guarantee that 
the identical muscles within each group weigh the same. This can be from muscle degeneration 
from old age or more percent body fat than muscle mass. Based on the data provided from these 
two studies and the weights and ages recorded within this study, donors can vary greatly in 
muscle function or muscle size when compared to each regardless of gender. By comparing 
skeletal muscle mass within male and female groups, more specifically young and old, male and 








The key findings of this study suggest: 
 Our group is the first to characterize human skeletal muscle extracellular matrix. 
 Location and gender do not have a significant effect on the yield, mechanics, and porosity 
characteristics of human skeletal muscle extracellular matrix. 
 Gender within the rectus femoris skeletal muscle extracellular matrix does have a 
significant effect on the network alignment. The overall location and gender does not 
have a significant effect on the network alignment of human skeletal muscle extracellular 
matrix.  
 Location (upper limb muscle vs. lower limb muscle) and gender does have a significant 
effect on the chemical characteristics of human skeletal muscle extracellular matrix. 
 The human skeletal muscle extracellular matrix can be tolerated within an in-vivo animal 
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Fig. 1. Representative image of whole human RF (A) and SS (B). Average weights of whole RF 
and SS used for characterization tests in grams (C). Data is presented as mean ± standard 
deviation. Significant difference (P = 0.001) was recorded between whole RF and SS weight 









Table 1. Average age of all muscles used for characterization tests. Data is presented as mean ± 
standard deviation. Number of skeletal muscles used for characterization tests were RF, n = 16 






Comparison of tissue age in Rectus Femoris and Supraspinatus 
Average Age Female Male Age Range 
Rectus Femoris 70.0 ± 22.1 65.4 ± 22.2 74.6 ± 22.5 24 - 98







Fig. 2. Progressive decellularization RF samples at Day 0, 5, and 15 (A-C). Fluorescently stained 
nuclei (DAPI-Blue) and intercellular actin (Phalloidin-Red) in non-decellularized (D) native RF 











Fig. 3. Representation of yield RF ECM from decellularization protocol (A). SEM representation 
image of RF ECM at 200x (B). Average ECM yield (g ECM/g whole muscle) for all groups (C). 
Data presented as mean ± the standard error of the mean. No significant difference reported. 











Fig. 4. Representative of collagen (green) in RF ECM (A). Average collagen composition for all 
groups (B). Data presented as mean ± the standard error of the mean. Significant difference 
between location was recorded (P<0.05) between the RF ECM and SS ECM using a 2-way 








Fig. 5. Representative of chondroitin sulfate proteoglycan (GAG-red) in RF ECM (A). Average 
GAG composition for all groups (B). Data presented as mean ± the standard error of the mean. 
Significant difference for the overall gender regardless of location was recorded (P<0.05) for the 











Fig. 6. Representative of porosity (A) and oriented angle (B) in RF ECM (100x). Scale bars are 
100 um. Average porosity (% open space) (C) and oriented angle (degrees) (D) for all groups. 
Data presented as mean ± the standard error of the mean. Significant difference (P<0.05) was 
recorded between gender of the RF ECM group using a student t-test with equal variance 










Fig. 7. Stress (kPa) / Strain (mm/mm) curves for overall modulus of elasticity with red 
representing RF ECM and green representing SS ECM (A). Overall Modulus of Elasticity (kPa) 
(B) and Modulus of Elasticity (kPa) at 10% strain (C) were identified from the corresponding 
stress/strain curves. No significant difference was reported. Data presented as mean ± the 







Fig. 8. Representative of mice after initial implantation of RF ECM pellet (A) with an inset 
representing the size of the ECM pellet. The scale bar within the inset is 5 mm. Degradation 
curve with the average diameter of the ECM (mm) at 3 time points (0, 4, and 8 weeks) (B). The 
half-life of the ECM pellet is 3.83 weeks. Data presented as mean ± the standard error of the 
mean. Photo by author. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
